• Structure Therapeutics’ third-quarter 2026 net loss more than doubled year-over-year to $144.76 million.
• Research and development expenses more than doubled year-over-year to $134.55 million, due to higher clinical trial, preclinical development and employee costs.
• Cash, cash equivalents and short-term investments totaled $1.24 billion at September 30, 2026.
• Existing funds are expected to support operations and key clinical milestones through 2028, excluding additional pre-commercialization costs.
• Phase 3 aleniglipron trials are enrolling, with topline data expected in the second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091605PRIMZONEFULLFEED9873526) on November 09, 2026, and is solely responsible for the information contained therein.